Viokace Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increasing diagnosis of exocrine pancreatic insufficiency, rising prevalence of chronic pancreatitis, advancements in enzyme formulation stability, expanded clinician awareness of malabsorption disorders, availability of prescription enzyme therapies.

The growth in the forecast period can be attributed to increasing demand for long-term digestive support therapies, expansion of personalized dosing regimens, growing geriatric population with digestive disorders, rising focus on nutrition optimization, increasing access to specialty gastrointestinal treatments. Major trends in the forecast period include increasing use of enzyme replacement therapies, rising focus on digestive disorder management, growing adoption of pancreatic enzyme supplements, expansion of chronic pancreatitis treatment protocols, enhanced patient adherence support.

The rising prevalence of pancreatic disorders is expected to drive the growth of the Viokace market going forward. Pancreatic disorders encompass a variety of medical conditions affecting the pancreas, an organ responsible for producing digestive enzymes and hormones such as insulin. The increase in these disorders is attributed to factors like aging populations, unhealthy lifestyles, rising obesity rates, and the growing incidence of diseases such as diabetes that impact pancreatic function. Viokace supports the management of pancreatic disorders by supplying digestive enzymes that aid in the breakdown of fats, proteins, and carbohydrates, which is critical for patients with conditions like chronic pancreatitis or cystic fibrosis, where the pancreas cannot secrete adequate enzymes for proper digestion and nutrient absorption. For instance, in February 2023, according to Cancer Research UK, the incidence of pancreatic cancer in the UK is projected to increase by 5% between 2023-2025 and 2038-2040, reaching an average of 19 cases per 100,000 people annually by 2038-2040. Therefore, the rising prevalence of pancreatic disorders is driving the growth of the Viokace market.

Rising healthcare expenditure is expected to propel the growth of the Viokace market. Healthcare expenditure includes the total financial resources spent on healthcare services, treatments, infrastructure, and personnel by governments, individuals, and private entities. Factors such as aging populations, higher prevalence of chronic diseases, advances in medical technology, and increasing demand for healthcare contribute to rising expenditure. Increased healthcare spending enhances access to treatments like Viokace by improving affordability, availability, and reimbursement policies. For instance, in May 2024, according to the UK Office for National Statistics, total healthcare expenditure grew by 5.6% in nominal terms from 2022 to 2023, up from a 0.9% increase in 2022. Therefore, rising healthcare expenditure is driving the growth of the Viokace market.

The increasing geriatric population is expected to drive the growth of the Viokace market. The geriatric population, typically adults aged 65 and older, often faces unique health, social, and economic challenges. This population is expanding due to longer life expectancy and declining birth rates. Viokace benefits older adults by providing pancreatic enzymes that improve digestion and nutrient absorption, addressing pancreatic insufficiency related to aging or chronic conditions such as pancreatitis, and enhancing overall digestive health and quality of life. For instance, in 2024, according to the United Nations Department of Economic and Social Affairs, in 2023, ten of today’s least developed countries had over 1 million older persons, and by 2050 this number is projected to rise to 27, including two countries with more than 10 million older adults. Therefore, the increasing geriatric population is driving the growth of the Viokace market.

Major companies operating in the viokace market are AbbVie Inc.

North America was the largest region in the viokace market in 2025. The regions covered in the viokace market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the viokace market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are influencing the viokace market by increasing costs of imported enzyme raw materials, pharmaceutical-grade excipients, formulation equipment, and specialized packaging components. Hospital and retail pharmacies in North America and Europe are most affected due to reliance on imported active ingredients, while Asia-Pacific faces cost pressures in enzyme processing inputs. These tariffs are contributing to higher treatment costs and supply chain complexity. However, they are also encouraging regional enzyme manufacturing, local formulation capabilities, and strengthened domestic pharmaceutical supply chains.

The viokace market research report is one of a series of new reports that provides viokace market statistics, including viokace industry global market size, regional shares, competitors with a viokace market share, detailed viokace market segments, market trends and opportunities, and any further data you may need to thrive in the viokace industry. This viokace market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Viokace is a prescription medication containing pancrelipase, an enzyme replacement therapy used to treat exocrine pancreatic insufficiency (EPI) in patients with conditions such as chronic pancreatitis or cystic fibrosis. It aids digestion by supplementing the body’s natural pancreatic enzymes, improving nutrient absorption and reducing symptoms like malabsorption and weight loss.

The primary indications for Viokace include exocrine pancreatic insufficiency, chronic pancreatitis, and other pancreatic disorders. Exocrine pancreatic insufficiency occurs when the pancreas does not produce sufficient digestive enzymes, causing difficulties in digesting food and absorbing nutrients. Viokace is distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and is used by adult and geriatric patients.

The viokace market consists of sales of pharmaceutical products, diagnostic reagents, and medical devices. This market also encompasses associated costs for distribution, healthcare professional services, and patient support programs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.